On 29 July 2004, orphan designation (EU/3/04/212) was granted by the European Commission to, Gentium S.p.A, Italy, for defibrotide for the treatment of hepatic veno-occlusive disease (VOD).
In January 2016, Gentium S.p.A. changed name to Gentium S.r.l.
Update: Defibrotide has been authorised in the EU as Defitelio since 18 October 2013.
More information on Defitelio can be found in the European public assessment report (EPAR) on the Agency's website.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of hepatic veno-occlusive disease
|Date of first decision||
|EU designation number||
Review of designation
During its meeting of 3 to 4 September 2013, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EU/3/04/212 for Defitelio (defibrotide) as an orphan medicinal product for the treatment of hepatic veno-occlusive disease. The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other satisfactory methods of treatment. The COMP recommended that the orphan designation of the medicine be maintained.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.